Novartis CEO says company to make heart failure drug Entresto at Singapore plant

Novartis ($NVS) will make its heart failure drug Entresto at a Singapore site starting this year, CEO Joe Jimenez told the Straits Times, adding that plans are also underway to expand contact lens manufacturing in the city-state. Jimenez said Entresto is "one of the most important products in the company's history." Novartis has deep ties to Singapore, with the CEO in town to attend the Singapore Summit forum and meet with executives on its contact lens manufacturing facility run by Alcon slated for a $95 million expansion, the Straits Times said. The company has also built a state-of-the-art biologics manufacturing facility among four plants and keeps its regional headquarters and commercial operations here as well as the Novartis Institute for Tropical Diseases. Report